A Study of Lanabecestat (LY3314814) in Early Alzheimer's Disease Dementia

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02972658
Recruitment Status : Terminated (An independent assessment concluded the trial was not likely to meet the primary endpoint upon completion and therefore, trial stopped for futility.)
First Posted : November 23, 2016
Last Update Posted : October 26, 2018
Information provided by (Responsible Party):
Eli Lilly and Company

Brief Summary:
This study is an extension of study I8D-MC-AZES (NCT02245737), the AMARANTH study. The purpose of this study is to evaluate the effectiveness of the study drug lanabecestat in participants with early Alzheimer's disease dementia at the time of entry into study I8D-MC-AZES.

Condition or disease Intervention/treatment Phase
Alzheimer's Disease Drug: Lanabecestat Phase 3

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 422 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Care Provider, Investigator)
Primary Purpose: Treatment
Official Title: A Randomized, Double-Blind, Delayed-Start Study of LY3314814 (AZD3293) in Early Alzheimer's Disease Dementia (Extension of Study AZES, The AMARANTH Study)
Actual Study Start Date : March 15, 2017
Actual Primary Completion Date : October 2, 2018
Actual Study Completion Date : October 2, 2018

Arm Intervention/treatment
Experimental: Lanabecestat Dose 1
Lanabecestat given orally.
Drug: Lanabecestat
Administered orally
Other Names:
  • LY3314814
  • AZD3293

Experimental: Lanabecestat Dose 2
Lanabecestat given orally.
Drug: Lanabecestat
Administered orally
Other Names:
  • LY3314814
  • AZD3293

Experimental: AZES Placebo Arm / AZFD Dose 1
Lanabecestat given orally.
Drug: Lanabecestat
Administered orally
Other Names:
  • LY3314814
  • AZD3293

Experimental: AZES Placebo Arm / AZFD Dose 2
Lanabecestat given orally.
Drug: Lanabecestat
Administered orally
Other Names:
  • LY3314814
  • AZD3293

Primary Outcome Measures :
  1. Delayed Start Analysis on the 13-item Alzheimer's Disease Assessment Scale - Cognitive Subscale (ADAS-Cog13) [ Time Frame: AZES Baseline through AZFD Week 26 ]
    Delayed start analysis on the ADAS-Cog13

Secondary Outcome Measures :
  1. Delayed Start Analysis on the Alzheimer´s Disease Cooperative Study Activities of Daily Living Inventory (ADCS-iADL) Instrumental Items [ Time Frame: AZES Baseline through AZFD Week 26 ]
    Delayed start analysis on the ADCS-iADL instrumental items

  2. Delayed Start Analysis on the Functional Activities Questionnaire (FAQ) Score [ Time Frame: AZES Baseline through AZFD Week 26 ]
    Delayed start analysis on the FAQ score

  3. Delayed Start Analysis on the Integrated Alzheimer's Disease Rating Scale (iADRS) Score [ Time Frame: AZES Baseline through AZFD Week 26 ]
    Delayed start analysis on the iADRS score

  4. Delayed Start Analysis on the Mini-Mental Status Examination (MMSE) [ Time Frame: AZES Baseline through AZFD Week 26 ]
    Delayed start analysis on the MMSE

  5. Delayed Start Analysis on the ADAS-Cog13 [ Time Frame: AZES Baseline through AZFD Week 52 ]
    Delayed start analysis on the ADAS-Cog13

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   55 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Participants previously enrolled in AMARANTH (NCT02245737) who meet eligibility criteria for delayed start I8D-MC-AZFD.

Exclusion Criteria:

  • Participants who participate in AMARANTH (NCT02245737) who develop new conditions precluding them from enrolling into I8D-MC-AZFD.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT02972658

  Hide Study Locations
United States, Arizona
Banner Alzheimer's Institute
Phoenix, Arizona, United States, 85006
Territory Neurology & Research Institute
Tucson, Arizona, United States, 85704
United States, California
Pacific Research Network Inc
San Diego, California, United States, 92103
United States, Colorado
Mile High Research Center
Denver, Colorado, United States, 80218
United States, Connecticut
Institute for Neurodegenerative Disorders
New Haven, Connecticut, United States, 06510
United States, District of Columbia
Georgetown University Medical Center
Washington, District of Columbia, United States, 20057
United States, Florida
Brain Matters Research
Delray Beach, Florida, United States, 33445
Compass Research
Orlando, Florida, United States, 32806
IMIC, Inc.
Palmetto Bay, Florida, United States, 33157
Suncoast Neuroscience Associates
Saint Petersburg, Florida, United States, 33713
Roskamp Institute
Sarasota, Florida, United States, 34243
Premiere Research Institute at Palm Beach Neurology
West Palm Beach, Florida, United States, 33407
United States, Georgia
The Multiple Sclerosis Center of Atlanta
Atlanta, Georgia, United States, 30327
United States, Illinois
University of Chicago Medical Center
Chicago, Illinois, United States, 60637
United States, Indiana
Community Clinical Research Center
Anderson, Indiana, United States, 46011
United States, Massachusetts
Boston Center for Memory
Newton, Massachusetts, United States, 02459
United States, Mississippi
Hattiesburg Clinic
Hattiesburg, Mississippi, United States, 39401
United States, New Jersey
Memory Enhancement Center of America, Inc.
Eatontown, New Jersey, United States, 07724
The Cognitive and Research Center of NJ
Springfield, New Jersey, United States, 07081
Advanced Memory Research Institute of New Jersey
Toms River, New Jersey, United States, 08755
United States, New York
Integrative Clinical Trials, LLC
Brooklyn, New York, United States, 11229
Columbia University Medical Center
New York, New York, United States, 10032
University of Rochester School of Medicine
Rochester, New York, United States, 14620
United States, Ohio
Valley Medical Primary Care
Centerville, Ohio, United States, 45459
Lindner Research Center
Cincinnati, Ohio, United States, 45219
Ohio State University Medical Center
Columbus, Ohio, United States, 43210
United States, Pennsylvania
Lehigh Valley Hospital
Allentown, Pennsylvania, United States, 18103
United States, Rhode Island
Rhode Island Mood & Memory Research Institute
East Providence, Rhode Island, United States, 02914
United States, South Carolina
Radiant Research
Greer, South Carolina, United States, 29651
United States, Tennessee
Quillen College of Medicine, East TN State University
Johnson City, Tennessee, United States, 37604
United States, Vermont
The Memory Clinic
Bennington, Vermont, United States, 05201
Australia, New South Wales
Southern Neurology
Kogarah, New South Wales, Australia, 2217
Australia, South Australia
Royal Adelaide Hospital
Adelaide, South Australia, Australia, 5000
Australia, Victoria
Eastern Clinical Research Unit
Box Hill, Victoria, Australia, 3128
Delmont Private Hospital
Glen Iris, Victoria, Australia, 3146
The Florey Institute of Neuroscience and Mental Health
Parkville, Victoria, Australia, 3052
Australia, Western Australia
Australian Alzheimer's Research Foundation
Nedlands, Western Australia, Australia, 6009
Neuro Trials Victoria Pty Ltd
Noble Park, Australia, 3174
Jessa Ziekenhuis
Hasselt, Limburg, Belgium, 3500
Hopital Universitaire Brugmann Brussel
Brussels, Belgium, 1020
Cliniques Universitaires Saint-Luc
Brussels, Belgium, 1200
Hospital Universitaire Erasme Brussel
Brussel, Belgium, 1070
Universitaire Ziekenhuizen Leuven - Campus Gasthuisberg
Leuven, Belgium, 3000
AZ Delta
Roeselare, Belgium, 8800
Canada, British Columbia
Okanagan Clinical Trials
Kelowna, British Columbia, Canada, V1Y 1Z9
Canada, Nova Scotia
True North Clinical Research Halifax, LLC
Halifax, Nova Scotia, Canada, B3S1M7
Canada, Ontario
Elizabeth Bruyere Health Centre
Ottawa, Ontario, Canada, KIN 5C8
Kawartha Regional Memory Clinic
Peterborough, Ontario, Canada, K9H2P4
Toronto Memory Program
Toronto, Ontario, Canada, M3B 2S7
Canada, Quebec
Clinique de la Memoire de l'Outaouais
Gatineau, Quebec, Canada, J8T 8J1
NeuroSearch Developements
Greenfield Park, Quebec, Canada, J4V 2J2
Hopital de L'Enfant Jesus
Quebec City, Quebec, Canada, G1J 1Z4
Q&T Research Sherbrooke Inc
Sherbrooke, Quebec, Canada, J1J 2G2
Centre Hospitalier Universitaire La Timone
Marseille, Cedex 05, France, 13385
CHRU de Lille- Hôpital Roger Salengro
Lille, Cedex, France, 59037
CHU de Toulouse Hopital Purpan
Toulouse, Cedex, France, 31059
Hopital Neuro Pierre Wertheimer
Bron Cedex, France, 69677
Chu de Nantes Hopital Laennec
Cedex 1, France, 44093
Dijon, France, 21079
Hopital Broca
Paris, France, 75013
Hôpital de la Pitié-Salpêtrière
Paris, France, 75013
Hôpital Fernand Widal
Paris, France, 75475
Centre de Recherche Clinique du Gérontopôle Cité de la Santé
Toulouse, France, 31052
Hopital des Charpennes
Villeurbanne, France, 69100
Universitätsklinikum Ulm
Ulm, Baden-Württemberg, Germany, 89081
Studien und Gedächtniszentrum München
München, Bayern, Germany, 80331
Klinikum Rechts der Isar der TU München
München, Bayern, Germany, 81675
Gemeinschaftspraxis für Neurologie und Psychiatrie
Westerstede, Niedersachsen, Germany, 26655
DataMed Klinische Studien GmbH
Köln, Nordrhein-Westfalen, Germany, 50935
Universitätsklinikum Köln
Köln, Nordrhein-Westfalen, Germany, 50937
Neurologische Praxis Siegen
Siegen, Nordrhein-Westfalen, Germany, 57076
Pharm Studienzentrum Chemnitz
Mittweida, Sachsen, Germany, 09648
Charité Universitätsmedizin Berlin
Berlin, Germany, 10117
Charité Universitätsmedizin Berlin
Berlin, Germany, 12203
SE Neurologiai Klinika
Budapest, Hungary, 1083
National Institute for Longevity Sciences NCGG
Obu, Aichi, Japan, 474-0038
National Chiba-East-Hospital
Chuo-ku, Chiba, Japan, 260-8712
Tsukuba University Hospital
Tsukuba, Ibaraki, Japan, 305-8576
Iwate Medical University Hospital
Morioka, Iwate, Japan, 020-8505
Nihon Kokan Hospital
Kawasaki, Kanagawa, Japan, 210-0852
Katayama Medical Clinic
Kurashiki, Okayama, Japan, 701-0192
Shiroma Clinic
Urasoe, Okinawa, Japan, 901-2102
Sakaguchi Clinic
Sakai, Osaka, Japan, 593-8301
National Sanatorium Toneyama Hospital
Toyonaka, Osaka, Japan, 560-8552
Memory Clinic Ochanomizu
Bunkyo-ku, Tokyo, Japan, 113-0034
Nippon Medical School Hospital
Bunkyo-Ku, Tokyo, Japan, 113-8603
The University of Tokyo Hospital
Bunkyo-ku, Tokyo, Japan, 113-8655
Tokyo Women's Medical University Hospital
Shinjuku-ku, Tokyo, Japan, 162-8666
National Sanatorium Hokuriku Hospital
Nanto, Toyama, Japan, 939-1893
Fukuoka University Hospital
Fukuoka, Japan, 814-0180
Kyoto University Hospital
Kyoto, Japan, 606-8507
Utano Hospital
Kyoto, Japan, 616-8255
Osaka City University Hospital
Osaka, Japan, 637086
Korea, Republic of
Dong-A University Medical Center
Seo-gu, Busan, Korea, Republic of, 49201
Hanyang University Guri Hospital
Guri-si, Gyeonggido, Korea, Republic of, 11923
Inha University Hospital
Jung-gu, Incheon, Korea, Republic of, 22332
Samsung Medical Center
Seoul, Korea, Korea, Republic of, 06351
Asan Medical Center
Songpa-gu, Seoul, Korea, Republic of, 05505
Gachon University Gil Medical Center
Incheon, Korea, Republic of, 21565
Seoul St. Mary's Hospital
Seoul, Korea, Republic of, 06591
Podlaskie Centrum Psychogeriatrii
Białystok, Podlaskie, Poland, 15-732
NZOZ Dom Sue Ryder - Pallmed Sp. z o.o.
Bydgoszcz, Poland, 85-796
NZOZ Wielospecjalistyczna Poradnia Lekarska
Katowice, Poland, 40-123
Centrum Zdrowia Psychicznego Biomed - Jan Latala
Kielce, Poland, 25-411
Krakowska Akademia Neurologii
Krakow, Poland, 31-505
Medycyna Milorzab
Lodz, Poland, 93-118
Instytut Medycyny Wsi
Lublin, Poland, 20-950
Centrum Medyczne Neuroprotect
Warszawa, Poland, 01-697
Puerto Rico
Santa Cruz Behavioral PSC
Bayamón, Puerto Rico, 00961-6911
SC Med Life SA
Bucuresti, Romania, 010719
SC Centrul Medical Sana SRL
Bucuresti, Romania, 011025
Hospital General Universitario de Elche
Elche, Alicante, Spain, 03203
Hospital Universitari de Bellvitge
Hospitalet de Llobregat, Barcelona, Spain, 08907
Hospital Virgen Del Puerto
Plasencia, Caceres, Spain, 10600
Hospital Universitario De Getafe
Madrid, Getafe, Spain, 28905
CITA Alzheimer
San Sebastian, Guipuzcoa, Spain, 20009
Hospital Son Espases
Son Espases, Palma De Mallorca, Spain, 07010
Centro de Atencion Especializada (CAE) OROITU
Getxo, Vizcaya, Spain, 48993
Fundacion ACE-Institut Catala de Neurociences Aplicades
Barcelona, Spain, 08014
Hospital Santa Creu I Sant Pau
Barcelona, Spain, 08025
Hospital Clinic I Provincial
Barcelona, Spain, 08036
Hospital De La Princesa
Madrid, Spain, 28006
Hospital Universitario Ramon y Cajal
Madrid, Spain, 28034
Hospital Universitario Dr Pesset
Valencia, Spain, 46017
Hospital Universitario La Fe de Valencia
Valencia, Spain, 46026
United Kingdom
Glasgow Memory Clinic
Scotland, Glasgow, United Kingdom, G20 0XA
Re-Cognition Health Ltd
London, Greater London, United Kingdom, W1G 9JF
MAC Clinical Research-Manchester
Manchester, Greater Manchester, United Kingdom, M13 9NQ
MAC Clinical Research
Blackpool, Lancashire, United Kingdom, FY2 0JH
West London Mental Health NHS Trust
Isleworth, London, United Kingdom, TW7 6FY
MAC Clinical Research
Cannock, Staffordshire, United Kingdom, WS11 0BN
Re-Cognition Health Ltd
Guildford, Surrey, United Kingdom, GU2 7YD
MAC Clinical Research
Leeds, United Kingdom, LS10 1DU
Sponsors and Collaborators
Eli Lilly and Company
Study Director: Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST) Eli Lilly and Company

Additional Information:
Responsible Party: Eli Lilly and Company Identifier: NCT02972658     History of Changes
Other Study ID Numbers: 16557
I8D-MC-AZFD ( Other Identifier: Eli Lilly and Company )
2016-003440-36 ( EudraCT Number )
First Posted: November 23, 2016    Key Record Dates
Last Update Posted: October 26, 2018
Last Verified: October 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Plan Description:

Lilly provides access to the individual patient data from studies on approved medicines and indications as defined by the sponsor specific information on

This access is provided in a timely fashion after the primary publication is accepted. Researchers need to have an approved research proposal submitted through Access to the data will be provided in a secure data sharing environment after signing a data sharing agreement.

Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No

Keywords provided by Eli Lilly and Company:
Alzheimer's Disease
Brain Diseases
Neurodegenerative Diseases
Central Nervous System Diseases
Nervous System Diseases
Mental Disorders
Delirium, Dementia, Amnestic, Cognitive Disorders

Additional relevant MeSH terms:
Alzheimer Disease
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Neurodegenerative Diseases
Neurocognitive Disorders
Mental Disorders